Immunoprecise Historical Financial Ratios

IPA Stock

USD 0.56 0.01 1.75%

Immunoprecise Antibodies is lately reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.41 or Invested Capital of 0.0 will help investors to properly organize and evaluate Immunoprecise Antibodies financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

About Immunoprecise Financial Ratios Analysis

Immunoprecise AntibodiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunoprecise Antibodies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunoprecise financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunoprecise Antibodies history.

Immunoprecise Antibodies Financial Ratios Chart

At present, Immunoprecise Antibodies' Average Payables is projected to decrease significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 19.53, whereas Price To Sales Ratio is forecasted to decline to 0.11.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Average Payables Net Income Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Immunoprecise Antibodies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunoprecise Antibodies sales, a figure that is much harder to manipulate than other Immunoprecise Antibodies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Immunoprecise Antibodies dividend as a percentage of Immunoprecise Antibodies stock price. Immunoprecise Antibodies dividend yield is a measure of Immunoprecise Antibodies stock productivity, which can be interpreted as interest rate earned on an Immunoprecise Antibodies investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from Immunoprecise Antibodies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Average Payables is projected to decrease significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 19.53, whereas Price To Sales Ratio is forecasted to decline to 0.11.

	2020	2021	2022	2023 (projected)
Payables Turnover	2.12	1.76	2.69	2.85
Days Of Inventory On Hand	68.95	70.33	82.61	62.63

Payables Turnover Days Of Inventory On Hand

Immunoprecise Antibodies fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding
Price To Sales Ratio		-0.62	0.79	0.1	0.79	-0.3	-0.41	0.2	-0.18	0.79	0.99	-0.5	-0.56	-0.7	-0.61	0.57	-0.35	0.39	0.77	0.74	-0.6	0.36	-0.47	-0.62	-0.61	0.3
Dividend Yield	-0.62		-0.75	0.38	-0.22	0.35	0.27	0.0	-0.45	-0.75	-0.63	0.38	0.55	0.57	0.67	-0.19	0.48	-0.11	-0.89	-0.22	0.12	-0.32	0.28	0.39	0.14	-0.46
Ptb Ratio	0.79	-0.75		0.04	0.52	-0.12	-0.19	0.12	-0.07	1.0	0.81	-0.29	-0.68	-0.65	-0.56	0.47	-0.17	0.41	0.84	0.39	-0.3	0.45	-0.34	-0.39	-0.35	0.15
Days Sales Outstanding	0.1	0.38	0.04		0.05	0.3	0.05	0.5	-0.8	0.04	0.12	0.09	0.22	0.24	0.1	-0.04	0.43	0.03	-0.04	-0.03	-0.02	-0.17	0.47	0.29	-0.08	-0.47
Book Value Per Share	0.79	-0.22	0.52	0.05		-0.12	-0.53	-0.11	-0.42	0.52	0.75	-0.57	-0.54	-0.67	-0.52	0.72	-0.13	0.33	0.44	0.79	-0.51	0.22	-0.57	-0.43	-0.48	0.05
Free Cash Flow Yield	-0.3	0.35	-0.12	0.3	-0.12		0.52	0.01	-0.2	-0.12	-0.33	0.54	-0.09	0.44	0.44	-0.3	0.26	-0.17	-0.27	-0.08	0.14	0.39	0.47	0.24	0.22	-0.28
Operating Cash Flow Per Share	-0.41	0.27	-0.19	0.05	-0.53	0.52		-0.09	0.17	-0.19	-0.45	0.99	0.26	0.55	0.69	-0.57	0.18	0.04	-0.36	-0.09	-0.15	0.37	0.5	-0.13	-0.13	-0.15
Average Payables	0.2	0.0	0.12	0.5	-0.11	0.01	-0.09		-0.06	0.12	0.29	-0.06	-0.02	0.03	0.06	-0.13	-0.38	-0.16	0.03	-0.21	0.15	0.12	0.0	0.2	0.13	0.43
Capex To Depreciation	-0.18	-0.45	-0.07	-0.8	-0.42	-0.2	0.17	-0.06		-0.07	-0.18	0.13	-0.06	0.03	0.1	-0.41	-0.65	-0.26	0.04	-0.21	0.14	0.24	-0.17	-0.2	0.19	0.71
Pb Ratio	0.79	-0.75	1.0	0.04	0.52	-0.12	-0.19	0.12	-0.07		0.81	-0.29	-0.68	-0.65	-0.56	0.47	-0.17	0.41	0.84	0.39	-0.3	0.45	-0.34	-0.39	-0.35	0.15
Ev To Sales	0.99	-0.63	0.81	0.12	0.75	-0.33	-0.45	0.29	-0.18	0.81		-0.54	-0.6	-0.74	-0.64	0.59	-0.35	0.4	0.78	0.64	-0.52	0.33	-0.52	-0.55	-0.54	0.31
Free Cash Flow Per Share	-0.5	0.38	-0.29	0.09	-0.57	0.54	0.99	-0.06	0.13	-0.29	-0.54		0.34	0.62	0.76	-0.6	0.22	0.0	-0.47	-0.16	-0.09	0.31	0.53	-0.04	-0.07	-0.19
Roic	-0.56	0.55	-0.68	0.22	-0.54	-0.09	0.26	-0.02	-0.06	-0.68	-0.6	0.34		0.67	0.54	-0.52	0.24	-0.29	-0.55	-0.26	0.17	-0.53	0.57	0.29	0.22	-0.24
Inventory Turnover	-0.7	0.57	-0.65	0.24	-0.67	0.44	0.55	0.03	0.03	-0.65	-0.74	0.62	0.67		0.66	-0.73	0.23	-0.45	-0.57	-0.38	0.27	-0.21	0.77	0.4	0.29	-0.24
Net Income Per Share	-0.61	0.67	-0.56	0.1	-0.52	0.44	0.69	0.06	0.1	-0.56	-0.64	0.76	0.54	0.66		-0.53	0.16	-0.03	-0.82	-0.22	0.04	0.18	0.35	0.16	0.09	-0.09
Days Of Inventory On Hand	0.57	-0.19	0.47	-0.04	0.72	-0.3	-0.57	-0.13	-0.41	0.47	0.59	-0.6	-0.52	-0.73	-0.53		0.22	0.63	0.35	0.38	-0.23	0.09	-0.67	-0.2	-0.25	-0.2
Payables Turnover	-0.35	0.48	-0.17	0.43	-0.13	0.26	0.18	-0.38	-0.65	-0.17	-0.35	0.22	0.24	0.23	0.16	0.22		0.4	-0.27	-0.24	0.12	-0.28	0.34	0.33	0.06	-0.98
Average Inventory	0.39	-0.11	0.41	0.03	0.33	-0.17	0.04	-0.16	-0.26	0.41	0.4	0.0	-0.29	-0.45	-0.03	0.63	0.4		0.13	0.3	-0.43	0.41	-0.45	-0.39	-0.49	-0.31
Capex To Revenue	0.77	-0.89	0.84	-0.04	0.44	-0.27	-0.36	0.03	0.04	0.84	0.78	-0.47	-0.55	-0.57	-0.82	0.35	-0.27	0.13		0.38	-0.24	0.17	-0.17	-0.38	-0.27	0.2
Cash Per Share	0.74	-0.22	0.39	-0.03	0.79	-0.08	-0.09	-0.21	-0.21	0.39	0.64	-0.16	-0.26	-0.38	-0.22	0.38	-0.24	0.3	0.38		-0.84	0.34	-0.29	-0.77	-0.78	0.13
Pocfratio	-0.6	0.12	-0.3	-0.02	-0.51	0.14	-0.15	0.15	0.14	-0.3	-0.52	-0.09	0.17	0.27	0.04	-0.23	0.12	-0.43	-0.24	-0.84		-0.23	0.24	0.92	0.96	-0.04
Interest Coverage	0.36	-0.32	0.45	-0.17	0.22	0.39	0.37	0.12	0.24	0.45	0.33	0.31	-0.53	-0.21	0.18	0.09	-0.28	0.41	0.17	0.34	-0.23		-0.23	-0.32	-0.23	0.34
Payout Ratio	-0.47	0.28	-0.34	0.47	-0.57	0.47	0.5	0.0	-0.17	-0.34	-0.52	0.53	0.57	0.77	0.35	-0.67	0.34	-0.45	-0.17	-0.29	0.24	-0.23		0.38	0.23	-0.4
Capex To Operating Cash Flow	-0.62	0.39	-0.39	0.29	-0.43	0.24	-0.13	0.2	-0.2	-0.39	-0.55	-0.04	0.29	0.4	0.16	-0.2	0.33	-0.39	-0.38	-0.77	0.92	-0.32	0.38		0.85	-0.27
Pfcf Ratio	-0.61	0.14	-0.35	-0.08	-0.48	0.22	-0.13	0.13	0.19	-0.35	-0.54	-0.07	0.22	0.29	0.09	-0.25	0.06	-0.49	-0.27	-0.78	0.96	-0.23	0.23	0.85		0.01
Days Payables Outstanding	0.3	-0.46	0.15	-0.47	0.05	-0.28	-0.15	0.43	0.71	0.15	0.31	-0.19	-0.24	-0.24	-0.09	-0.2	-0.98	-0.31	0.2	0.13	-0.04	0.34	-0.4	-0.27	0.01

Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	4.56	3.76	11.02	7.27	4.19	1.84
Ptb Ratio	2.76	3.5	3.47	1.87	1.5	1.33
Days Sales Outstanding	65.2	97.33	83.93	64.26	77.98	66.71
Book Value Per Share	1.44	1.11	3.46	3.82	2.32	1.32
Free Cash Flow Yield	(0.0772)	(0.0372)	(0.0103)	(0.0794)	(0.25)	(0.12)
Operating Cash Flow Per Share	(0.26)	(0.1)	(0.0364)	(0.5)	(0.8)	(0.17)
Stock Based Compensation To Revenue	0.0526	0.15	0.16	0.094	0.0626	0.0595
Capex To Depreciation	0.29	0.17	0.38	0.33	0.22	0.24
Pb Ratio	2.76	3.5	3.47	1.87	1.5	1.33
Ev To Sales	4.33	3.89	8.88	5.85	4.14	2.26
Free Cash Flow Per Share	(0.31)	(0.14)	(0.12)	(0.57)	(0.86)	(0.22)
Inventory Turnover	7.36	5.29	5.19	4.42	5.83	5.54
Net Income Per Share	(0.61)	(0.36)	(0.45)	(0.85)	(1.07)	(1.06)
Days Of Inventory On Hand	137.46	49.6	68.95	70.33	82.61	62.63
Payables Turnover	3.53	3.41	2.12	1.76	2.69	2.85
Sales General And Administrative To Revenue	0.7	0.57	0.71	0.88	0.96	0.64
Capex To Revenue	0.059	0.0409	0.0797	0.0649	0.0723	0.057
Cash Per Share	0.44	0.19	2.53	1.52	0.33	0.13
Pocfratio	(15.55)	(37.97)	(329.03)	(14.19)	(4.37)	(10.65)
Interest Coverage	(4.72)	(2.85)	(7.71)	(37.66)	(869.7)	(723.11)
Capex To Operating Cash Flow	(0.2)	(0.41)	(2.38)	(0.13)	(0.0754)	(0.33)
Pfcf Ratio	(12.95)	(26.86)	(97.4)	(12.59)	(4.06)	(8.01)
Days Payables Outstanding	103.32	107.01	172.42	207.65	135.78	128.02
Income Quality	0.42	0.28	0.0817	0.59	0.75	0.16
Roe	(0.42)	(0.33)	(0.13)	(0.22)	(0.46)	(0.8)
Ev To Operating Cash Flow	(14.76)	(39.34)	(265.2)	(11.42)	(4.32)	(13.06)
Pe Ratio	(8.46)	(6.55)	(10.68)	(26.9)	(8.42)	(3.26)
Return On Tangible Assets	(0.65)	(0.45)	(0.14)	(0.4)	(0.96)	(0.95)
Ev To Free Cash Flow	(12.29)	(27.83)	(78.5)	(10.14)	(4.02)	(9.82)
Net Debt To E B I T D A	0.65	(5.2)	211.61	2.26	0.0476	(1.28)
Current Ratio	1.37	0.97	8.05	4.05	2.84	1.41
Tangible Book Value Per Share	0.11	(0.0813)	2.62	1.18	0.31	0.1

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:

How To Invest In Immunoprecise

Details

Is Immunoprecise Stock a good investment?

Details

What is Immunoprecise Antibodies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.76)

Revenue Per Share

0.921

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.13)

Return On Equity

(0.64)

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Immunoprecise Historical Financial Ratios

About Immunoprecise Financial Ratios Analysis

Immunoprecise Antibodies Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Average Payables

Immunoprecise Antibodies fundamentals Correlations

Immunoprecise Antibodies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunoprecise Antibodies fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Ev To Sales	+ 0.99	Price To Sales Ratio
Free Cash Flow Per Share	+ 0.99	Operating Cash Flow Per Share
Pfcf Ratio	+ 0.96	Pocfratio
Capex To Operating Cash Flow	+ 0.92	Pocfratio
Pfcf Ratio	+ 0.85	Capex To Operating Cash Flow

Days Payables Outstanding	- 0.98	Payables Turnover
Capex To Revenue	- 0.89	Dividend Yield
Pocfratio	- 0.84	Cash Per Share
Capex To Revenue	- 0.82	Net Income Per Share
Capex To Depreciation	- 0.8	Days Sales Outstanding
Pfcf Ratio	- 0.78	Cash Per Share